PARP1 and ovarian cancer: While PARP inhibitors such as talazoparib are currently being used in clinics in patients with BRCA mutation (HR defective) breast and ovarian cancers, the inherent and acquired drug resistance to PARP inhibitors by the restoration of BRCA1/2 function (HR active) is the major challenge to successful therapy.